ArticleClinical cancer research : an official journal of the American Association for Cancer Research2011

Reduced dose and intermittent treatment with lapatinib and trastuzumab for potent blockade of the HER pathway in HER2/neu-overexpressing breast tumor xenografts.

Mothaffar F Rimawi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.